|Mr. William J. Gastle||Founder & Exec. Chairman||197.75k||N/A||N/A|
|Mr. Cameron Groome||Pres, CEO & Director||N/A||N/A||N/A|
|Mr. Philip Casselli||Sr. VP of Sales, Bus. Devel. and Marketing||179.54k||N/A||N/A|
|Mr. Vaughn C. Embro-Pantalony||Exec. Director||221.5k||N/A||N/A|
|Mr. Kevin J. Cassidy||VP of Biopharmaceuticals||150k||N/A||N/A|
Microbix Biosystems Inc. develops and commercializes biological and technology solutions for human health and wellbeing North America, Europe, and internationally. It offers infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry; controls for molecular diagnostic assays; basic and applied research in virology, microbiology, cell biology, molecular biology, immunology, and pathology; as controls and calibrators for a range of medical devices; and for vaccine and antiviral research and development. The company also manufactures inactivated viral antigen detection proficiency testing samples; and unassayed control reagents for in vitro molecular diagnostic assays. Its pipeline of technologies and products include LumiSort semen sexing technology for the livestock industries and Kinlytic, a thrombolytic drug for the treatment of life-threatening pulmonary embolism and clot obstructed intravenous catheters. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.
Microbix Biosystems Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.